Discontinued — last reported Q2 '25
Business Segments · Goodwill acquired
U.S. Pharmaceutical — Goodwill acquired
McKesson U.S. Pharmaceutical — Goodwill acquired increased by 495100.0% to $1.24B in Q2 2025 compared to the prior quarter. Year-over-year, this metric grew by 495100.0%, from $250.00K to $1.24B. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ2 2019
Last reportedQ2 2025
How to read this metric
An increase indicates active inorganic growth and investment in expanding the segment's market footprint.
Detailed definition
This metric tracks the amount of new goodwill added to the U.S. Pharmaceutical segment balance sheet during the period d...
Peer comparison
Commonly reported by companies pursuing an active M&A strategy.
Metric ID:
mck_segment_u_s_pharmaceutical_goodwill_acquiredHistorical Data
14 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q4 '23 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | $0.00 | $0.00 | $40.00M | $40.00M | $40.00M | $40.00M | $0.00 | $250.00K | $250.00K | $250.00K | $250.00K | $1.24B |
| QoQ Change | — | — | — | — | — | +0.0% | +0.0% | +0.0% | -100.0% | — | +0.0% | +0.0% | +0.0% | >999% |
| YoY Change | — | — | — | — | — | — | — | — | -100.0% | — | — | — | — | >999% |
Range$0.00 – $1.24B
Avg YoY Growth>999%
Median YoY Growth>999%
Current Streak4+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — goodwill acquired?
- McKesson (MCK) reported u.s. pharmaceutical — goodwill acquired of $1.24B in Q2 2025.
- How has McKesson's u.s. pharmaceutical — goodwill acquired changed year-over-year?
- McKesson's u.s. pharmaceutical — goodwill acquired increased by 495100.0% year-over-year, from $250.00K to $1.24B.
- What does u.s. pharmaceutical — goodwill acquired mean?
- The value of goodwill added to the U.S. Pharmaceutical segment through new acquisitions.